CF
NMRA icon

Corebridge Financial’s Neumora Therapeutics NMRA Stock Holding History

Corebridge Financial’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,753
Closed -$41.8K – 1804
2025
Q1 		$41.8K Sell
41,753
-66
-0.2% -$113 ﹤0.01% 2775
2024
Q4 		$443K Sell
41,819
-3,157
-7% -$37.8K ﹤0.01% 1751
2024
Q3 		$594K Sell
44,976
-277
-0.6% -$3.23K ﹤0.01% 1639
2024
Q2 		$445K Buy
+45,253
New +$468K ﹤0.01% 1749

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Corebridge Financial's NMRA Position: Q2 2025 in Review

Corebridge Financial sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 41,753 shares — an estimated $41.8K sold.

Corebridge Financial first reported a position in NMRA in Q2 2024 and held it in 4 quarters. The position peaked at $594K in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Corebridge Financial reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 41,753 Neumora Therapeutics shares in Q2 2025, an estimated $41.8K.
  • Corebridge Financial first reported a position in Neumora Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Neumora Therapeutics position peaked at $594K in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.